Dr. Philip Reilly is a Venture Partner at Third Rock Ventures and has served as Chief Medical Officer (CMO) of Goldfinch Bio, co-founder of Fulcrum Therapeutics, co-founder and CMO of Voyager Therapeutics, CMO of Bluebird Bio, co-founder of Edimer, among other startup roles. He served as Chairman and CEO of Interleukin Genetics.

Phil has authored or co-authored more than 100 articles in scholarly journals and has published seven books including most recently Orphan: The Quest to Save Children with Rare Genetic Disorders. Phil currently serves on the Advisory Board to the Boston University School of Public Health, and has served as a trustee emeritus of Cornell University, and Overseer of Weill Cornell Medical College.  He earned his medical degree at the Yale School of Medicine.